Jacobson Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Jacobson Pharma has a total shareholder equity of HK$2.4B and total debt of HK$705.0M, which brings its debt-to-equity ratio to 29.4%. Its total assets and total liabilities are HK$3.5B and HK$1.1B respectively. Jacobson Pharma's EBIT is HK$311.4M making its interest coverage ratio 6.1. It has cash and short-term investments of HK$458.2M.
Anahtar bilgiler
29.4%
Borç/özkaynak oranı
HK$705.00m
Borç
| Faiz karşılama oranı | 6.1x |
| Nakit | HK$458.17m |
| Eşitlik | HK$2.40b |
| Toplam yükümlülükler | HK$1.09b |
| Toplam varlıklar | HK$3.49b |
Son finansal sağlık güncellemeleri
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Recent updates
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 2633's short term assets (HK$964.4M) exceed its short term liabilities (HK$372.8M).
Uzun Vadeli Yükümlülükler: 2633's short term assets (HK$964.4M) exceed its long term liabilities (HK$717.7M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 2633's net debt to equity ratio (10.3%) is considered satisfactory.
Borcun Azaltılması: 2633's debt to equity ratio has reduced from 48.3% to 29.4% over the past 5 years.
Borç Kapsamı: 2633's debt is well covered by operating cash flow (68.7%).
Faiz Kapsamı: 2633's interest payments on its debt are well covered by EBIT (6.1x coverage).